Development of next generation immunotherapies based on the BEAT platform.

• Responsabile for the study design, experimental management, result analysis/reporting and publication of pre-clinical exploratory investigation to define the efficacy and the mode of action of antibody based cancer immunotherapies at both pre-clinical and clinical stage. Projects include the study of immune-checkpoint inhibitors, glycoengineered antibodies (such as GAZYVA), T cell bispecifics platform (such as CEA-TCB and CD20-TCB) and other immune-stimulatory therapeutics.• Group Leader of Preclinical Imaging, Histology and Analytics Core focused on Cancer Immunotherapy. The accountabilities of the role include:1) In house development of innovative preclinical model to study cancer immune-therapy drugs in action.2) Management of all imaging, histology and analytics infrastructures, equipments, robotics and workflows.3) Initiate partnership opportunities with external businesses partners and academic excellence to implemented solutions and improvements in pre-clinical imaging, histology and analytics infrastructures, workflows and technical platform.4) Responsible for the filing of several business cases including execution of qualitative risk analysis, market research and due diligence to obtain successful approval to invest in cutting-edge scientific equipments.• Responsabile for the study design, experimental management, result analysis/reporting and publication of pre-clinical exploratory investigation to define the efficacy and the mode of action of antibody based cancer immunotherapies at both pre-clinical and clinical stage. Projects include the study of immune-checkpoint inhibitors, glycoengineered antibodies (such as GAZYVA/GAZYVARO), immunocytokine (such as IL2v platform), T cell bispecifics platform (such as CEA CD3 TCB) and other immune-stimulatory therapeutics.

• Preclinical Imaging Team Leader: Coordinate the Preclinical Imaging Team activities• Responsabile for the study design, experimental management, result analysis/reporting and publication of pre-clinical exploratory investigation.

Research Fellow at Harvard Medical School, Boston, USA (2011- present) funded by GSK fellowship.Immune Disease Institute & Dep. Microbiolody and Immunobiology. Supervisor: Ulrich von Andrian• In collaboration with GlaxoSmithKline I’m developing in vitro and in vivo assays to test the combinatorial efficacy of small molecules inhibiting migration of effector T cells to the gut for the treatment of Crohn’s disease. The project is finalized to develop tools to be employed for clinical trial studies and to collect pre-clinical data.• Developing new model for studying infections which leads to improved vaccine candidates: combining molecular approaches to intra-vital imaging techniques during infection response allow us to directly study the molecule involved in T cell activation in a physiological microenvironment. Molecules involved in T cell activation and memory formation can be specifically targeted to enhance their function and therefore used as adjuvants.

MRC/PhD at University College of London, UK (2006-2010) funded by Medical Research Council.Dep. of Immunology and Molecular Pathology. Supervisors: Prof. Hans Stauss and Dr. Emma Morris • Developing new Lentiviral gene transfer protocols in T cells to improve adoptive transfer for treatment of Leukemia of an ongoing clinical trial: 1) new Lentivirus designs that allow a strong bi-cistronic expression of α and β chain of TCR; 2) study the role of Homeostatic cytokines (IL2, IL7,IL15, IL21) on transduced T cell in human and murine system. The results are summarized in an international scientific journal (Perro M. et al., Pospori C. et al, and other papers).• Defining the genetic factors that may be responsible for Small Bowel Disease and Colitis. Focus on IL10 function. The results are summarized in an international scientific journal (Erik-Oliver Glocker,MD. et al 2009, Erik-Oliver Glocker,MD. et al 2010)

Research exchange at Harvard Medical School, Boston, USA (2009) funded by Bogue fellowship and Post-Graduate School research award.Department of Pathology, Supervisor: Ulrich von Andrian • Development of Adenoviral vector for transduction of Naïve T cells: application for 2-photon intra-vital imaging. These preliminary set of data have been used to successfully apply for a NIH grant that is now financing part of my present research.

Research assistant at the University of Turin, Italy (2003-2006) funded by personal funding.Department of Cancer Genetics, Institute for Treatment and Research of Cancer Supervisor: Di Renzo MF• Defining the genetic factors that may be responsible for multiple cutaneous and uterine leiomyoma (MCUL).Focus on the interplay between the oncogene MET tyrosine kinase and Fumarase. The results are summarized in an international scientific journal (Lorenzato, Olivero, Perro et al.)